Lacosamide

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H18N2O3
Molecular Weight	250.2936
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1

InChI

InChIKey=VPPJLAIAVCUEMN-GFCCVEGCSA-N

InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H18N2O3
Molecular Weight	250.2936
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204839s000lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/lacosamide.html | http://www.wikidoc.org/index.php/Lacosamide | https://www.ncbi.nlm.nih.gov/pubmed/17461888 | https://www.ncbi.nlm.nih.gov/pubmed/19552484

Lacosamide is an anticonvulsant that is FDA approved for the treatment of partial-onset seizures. The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing Common adverse reactions include diplopia, headache, dizziness, nausea. Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to Lacosamide tablets.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Voltage-gated sodium channels 1 Target ID: Voltage-gated sodium channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/17940193 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Blocker 537	164.0 µM [EC50]
Dihydropyrimidinase-related protein 2 4 Target ID: P47942 Gene ID: 25416.0 Gene Symbol: Dpysl2 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20538611 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Binding Agent 1064
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22850102	Substrate 661	1797.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Partial-onset seizures 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Primary		Approved 8429	VIMPAT Approved Use VIMPAT is indicated for: Partial-onset seizures (1.1): Tablets and oral solution are indicated for adjunctive therapy in patients ≥17 years. Injection is indicated as short term replacement when oral administration is not feasible in these patients. 1.1 Partial-Onset Seizures VIMPAT (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. VIMPAT (lacosamide) injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible. Launch Date 2008
Diabetic neuropathy 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19552484 https://www.ncbi.nlm.nih.gov/pubmed/17237664	Palliative		Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
2935.3 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
59120 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.47 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult n = 270 Health Status: unhealthy Condition: partial-onset seizures Age Group: adult Population Size: 270 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult n = 471 Health Status: unhealthy Condition: partial-onset seizures Age Group: adult Population Size: 471 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult n = 203 Health Status: unhealthy Condition: partial-onset seizures Age Group: adult Population Size: 203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
12 mg/kg 1 times / day multiple, oral (max) Studied dose Dose: 12 mg/kg, 1 times / day Route: oral Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	unhealthy, ≥1 month ≤17 years n = 21 Health Status: unhealthy Condition: focal seizures Age Group: ≥1 month ≤17 years Sex: M+F Population Size: 21 Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	Other AEs: Vomiting, Dizziness... Other AEs: Vomiting (4.8%) Dizziness (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/
5.82 mg/kg 1 times / day multiple, oral (mean) Dose: 5.82 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5.82 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	unhealthy, ≥1 month ≤17 years n = 47 Health Status: unhealthy Condition: focal seizures Age Group: ≥1 month ≤17 years Sex: M+F Population Size: 47 Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	Disc. AE: Vomiting, Gait disturbance... AEs leading to discontinuation/dose reduction: Vomiting (8.5%) Gait disturbance (6.4%) Dizziness (6.4%) Somnolence (6.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/
12 g single, oral Overdose Dose: 12 g Route: oral Route: single Dose: 12 g Co-administed with:: zonisamide topiramate gabapentin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Other AEs: Coma... Other AEs: Coma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
1200 mg 1 times / day multiple, oral Overdose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28926353	healthy n = 34 Health Status: healthy Sex: M+F Population Size: 34 Sources: https://pubmed.ncbi.nlm.nih.gov/28926353	Other AEs: Dysarthria, Dysphemia... Other AEs: Dysarthria (severe, 1 patient) Dysphemia (severe, 1 patient) Aphasia (severe, 1 patient) Negative thoughts (severe, 1 patient) Coordination abnormal (severe, 1 patient) Muscle weakness (severe, 2 patients) Nausea (severe, 2 patients) Vomiting (severe, 2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/28926353
100 mg 2 times / day steady, oral Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	unhealthy n = 72 Health Status: unhealthy Condition: Migraine Population Size: 72 Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	Other AEs: Myocardial infarction, Knee operation... Other AEs: Myocardial infarction (serious, 1 patient) Knee operation (serious, 1 patient) Diarrhoea (below serious, 4 patients) Fatigue (below serious, 5 patients) Nasopharyngitis (below serious, 12 patients) Bronchitis (below serious, 2 patients) Sinusitis (below serious, 4 patients) Upper respiratory tract infection (below serious, 7 patients) Dizziness (below serious, 5 patients) Oropharyngeal pain (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00440518
200 mg 2 times / day steady, oral Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00401830	unhealthy n = 78 Health Status: unhealthy Condition: Fibromyalgia Syndrome Population Size: 78 Sources: https://clinicaltrials.gov/ct2/show/NCT00401830	Other AEs: Vision blurred, Constipation... Other AEs: Vision blurred (below serious, 4 patients) Constipation (below serious, 5 patients) Hypoaesthesia oral (below serious, 4 patients) Nausea (below serious, 13 patients) Vomiting (below serious, 5 patients) Back pain (below serious, 4 patients) Pain in extremity (below serious, 4 patients) Balance disorder (below serious, 4 patients) Dizziness (below serious, 18 patients) Somnolence (below serious, 5 patients) Pruritus (below serious, 7 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00401830
300 mg 2 times / day steady, oral Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	unhealthy n = 74 Health Status: unhealthy Condition: Migraine Population Size: 74 Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	Other AEs: Coronary artery dissection, Vaginal infection... Other AEs: Coronary artery dissection (serious, 1 patient) Vaginal infection (serious, 1 patient) Fatigue (below serious, 11 patient) Nasopharyngitis (below serious, 11 patient) Bronchitis (below serious, 4 patients) Sinusitis (below serious, 3 patients) Oropharyngeal pain (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00440518
400 mg steady, oral (total daily dose) Dose: 400 mg Route: oral Route: steady Dose: 400 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00485472	unhealthy n = 72 Health Status: unhealthy Condition: Osteoarthritis Population Size: 72 Sources: https://clinicaltrials.gov/ct2/show/NCT00485472	Other AEs: Angina pectoris, Sick sinus syndrome... Other AEs: Angina pectoris (serious, 1 patient) Sick sinus syndrome (serious, 1 patient) Liver disorder (serious, 1 patient) Hypoglycaemic shock (serious, 1 patient) Breast cancer in situ (serious, 1 patient) Vertigo (below serious, 8 patients) Fatigue (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00485472

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781 inhibitor 1587	substrate 1037 inducer 389 inhibitor 1767	inhibitor 1852 substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 CYP1A1 110 CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2E1 882 CYP3A5 73 CYP2C19 1478	CYP2C19 991 P-gp 1537 CYP1A2 1054 CYP2B6 664 CYP2C8 693	CYP1A2 701 CYP2B6 547 CYP2C19 293

Drug as perpetrator

Target	Modality	Activity
CYP1A1 218	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
CYP3A5 130	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0	inconclusive	likely (co-administration study) Comment: POP-PK results showed that lacosamide exposure decreased 20% in the presence of carbamazepine, phenytoin, or phenobarbital Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46.0
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47.0	no
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 10, 46	yes	no (co-administration study) Comment: lacosamide had no effect on omeprazole PK Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 10, 46

Sourcing

Vendor/Aggregator	ID	URL
AEchem Scientific Corp., USA	AE1-014080	http://www.aechemsc.com/info_products/AE1-014080.php
AK Scientific, Inc. (AKSCI)	V0815	http://www.aksci.com/item_detail.php?cat=V0815
Achemtek	0102-030152	http://www.achemtek.com/175481-36-4
Acorn PharmaTech	ACN-046779	http://www.acornpharmatech.com/
Adooq BioScience	A10510	https://www.adooq.com/lacosamide.html
Alsachim	2251	http://www.alsachim.com/product-C3292-glo.bal-view.html
Ambinter	Amb13883599	http://www.ambinter.com/reference/13883599
Angene	AGN-PC-0O4YVA	http://www.angenechemical.com/productshow/AGN-PC-0O4YVA.html
Anward	ANW-58547	http://www.anward.com/pro_result/44998
AstaTech, Inc.	86269	http://www.astatechinc.com/CPSResult.php?CRNO=37844
Aurora Fine Chemicals LLC	A13.142.909	http://online.aurorafinechemicals.com/info?ID=A13.142.909
Aurum Pharmatech LLC	M-1600	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1600
AvaChem Scientific	2659	http://www.avachem.com/productSearch.asp?2659
Axon MedChem	1444	https://www.axonmedchem.com/product/1444
BenchChem	B532333	https://www.benchchem.com/product/b532333
BioChemPartner	BCP02197	http://www.biochempartner.com/175481-36-4-BCP02197
Chem Scene	CS-0529	http://www.chemscene.com/Lacosamide.html
ChemFish Tokyo co.,ltd	219078	http://www.chemfish.co.jp/index.php?id=2890&project=product
ChemMol	30115908	http://www.chemmol.com/chemmol/30115908.html
ChemMol	44014375	http://www.chemmol.com/chemmol/44014375.html
ChemMol	49400023	http://www.chemmol.com/chemmol/49400023.html
ChemMol	81402572	http://www.chemmol.com/chemmol/81402572.html
ChemMol	96705824	http://www.chemmol.com/chemmol/96705824.html
Chemenu	CM110363	http://www.chemenu.com/products/CM110363
Clearsynth	CS-O-31324	http://www.clearsynth.com/en/CSO31324.html
Enamine	Z1550648754	https://www.enaminestore.com/catalog/Z1550648754
LGC Standards	LGCAMP3640.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP3640.00-11
LGC Standards	LGCFOR3640.00	https://www.lgcstandards.com/US/en/p/LGCFOR3640.00
LGC Standards	MM3640.00-0250	https://www.lgcstandards.com/US/en/p/MM3640.00-0250
Lab Network	LN00220654	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00220654
MedChem Express	HY-13015	http://www.medchemexpress.com/Lacosamide.html
MolPort	MolPort-006-170-142	https://www.molport.com/shop/molecule-link/MolPort-006-170-142
OChem	25205	http://www.ocheminc.com/index.php?act=psearch&pid=481L364
Renno Tech	RL02246	http://www.rennotech.com/product_show.asp?id=2495
Sigma-Aldrich	L-029_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/l029?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S046322	http://www.sinfoobiotech.com/product/1049720
Smolecule	S532333	http://www.smolecule.com/products/s532333
Specs	AR-270/11402703	http://www.specs.net/enter.php?specsid=AR-270/11402703
Synblock Inc	SB18905	http://www.synblock.com/product/175481-36-4.html
THE BioTek	bt-272115	https://www.thebiotek.com/product/inhibitors/bt-272115
VladaChem	VL280235-1G	https://www.vladachem.com/product.php?products=175481-36-4
Yuhao Chemical	YH67130	http://www.chemyuhao.com/175481-36-4.html
abcr GmbH	AB437062	http://www.abcr.de/shop/en/AB437062
iChemical	EBD27785	http://www.ichemical.com/chemicals/cas-175481-36-4

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2004 Dec	15672123
Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain.	2006 Apr	15946870
Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury.	2006 Dec 28	17092498
New antiepileptic drugs that are second generation to existing antiepileptic drugs.	2006 Jun	16732716
Gateways to clinical trials.	2006 May	16801985
Gateways to clinical trials.	2006 Oct	17136234
Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain.	2007	17284318
Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.	2007 Apr	17360008
Management of painful diabetic neuropathy: what is new or in the pipeline for 2007?	2007 Dec	18255001
Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study.	2007 Feb	17237664
Lacosamide.	2007 Jan	17199030
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).	2007 Jan	17158031
Gateways to clinical trials.	2007 Jun	17805439
Lacosamide: a review of preclinical properties.	2007 Spring	17461888
Pharmacological management of epilepsy: recent advances and future prospects.	2008	18778117
Lacosamide.	2008 Dec	19043448
Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.	2008 Jan	18301802
Gateways to clinical trials.	2008 Mar	18560631
Painful diabetic neuropathy: treatment and future aspects.	2008 May-Jun	18395890
Lacosamide for the treatment of diabetic neuropathic pain.	2008 Nov	18986235
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.	2009	19552484
Lacosamide: in partial-onset seizures.	2009	19323588
Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.	2009 Aug	19409861
Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures.	2009 Jan	19102666
Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care.	2009 Jun	19949568
Lacosamide for epilepsy.	2009 Jun 29	19556941
Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany.	2009 Nov	19767242
Lacosamide: new drug. Refractory partial epilepsy: optimise existing combinations.	2009 Oct	19882781
Pharmacology and treatment of neuropathic pains.	2009 Oct	19741531
Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy.	2009 Sep	19573541
Lacosamide: what can be expected from the next new antiepileptic drug?	2009 Sep-Oct	19826503
A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy.	2010 Aug	20386357
In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.	2010 Aug 13	20538611
New Drugs2010, PART 1.	2010 Feb	20083979
Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide.	2010 Feb	19674050
Update on anticonvulsant drugs.	2010 Jul	20490745
Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.	2010 Jun	20199516
Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures.	2010 Jun	20041945
Proteomic searches comparing two (R)-lacosamide affinity baits: An electrophilic arylisothiocyanate and a photoactivated arylazide group.	2010 Jun 21	20405068
LOCF approach to handling missing data overestimates the pain score improvement of drop-outs.	2010 May	20338823

Patents

Sample Use Guides

In Vivo Use Guide

Initially, give 50 mg twice daily (100 mg/day). The dose may be increased, based on clinical response and tolerability, at weekly intervals by 100 mg/day given as two divided doses to a daily dose of 200 to 400 mg/day.

Route of Administration: Other

In Vitro Use Guide

In recombinant systems the effect of LCM on the potassium current mediated by the human hERG channel was studied. Inhibition of this channel has been associated with fatal arrhythmias. LCM only minimally affected hERG current at concentrations as high as 3000 uM/L.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:13:24 GMT 2023` Edited by `admin` on `Fri Dec 15 16:13:24 GMT 2023`
Record UNII	563KS2PQY5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Lacosamide

Official Name

English

Lacosamide [WHO-DD]

Common Name

English

LACOSAMIDE [EMA EPAR]

Common Name

English

LACOSAMIDE [VANDF]

Common Name

English

LACOSAMIDE [USP MONOGRAPH]

Common Name

English

SPM927

Code

English

ERLOSAMIDE

Common Name

English

Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-

Systematic Name

English

LACOSAMIDE [USAN]

Common Name

English

(+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE

Systematic Name

English

(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide

Systematic Name

English

VIMPAT

Brand Name

English

LACOSAMIDE [MART.]

Common Name

English

MOTPOLY

Brand Name

English

LACOSAMIDE [USP-RS]

Common Name

English

lacosamide [INN]

Common Name

English

ADD243037

Code

English

LACOSAMIDE [MI]

Common Name

English

LACOSAMIDE [EP MONOGRAPH]

Common Name

English

LACOSAMIDE [ORANGE BOOK]

Common Name

English

ADD-243037

Code

English

(R)-LACOSAMIDE 1

Common Name

English

SPM-927

Code

English

LACOSAMIDE [JAN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000008486